Bruker (NASDAQ:BRKR) Price Target Cut to $77.00

Bruker (NASDAQ:BRKR - Get Free Report) had its price target cut by research analysts at Stifel Nicolaus from $81.00 to $77.00 in a report released on Monday, Benzinga reports. The firm currently has a "hold" rating on the medical research company's stock. Stifel Nicolaus' price target would suggest a potential upside of 0.69% from the stock's current price.

BRKR has been the subject of a number of other reports. UBS Group lifted their target price on Bruker from $94.00 to $102.00 and gave the stock a "buy" rating in a report on Friday, March 1st. JPMorgan Chase & Co. upgraded Bruker from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. Citigroup lifted their target price on Bruker from $80.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, February 14th. Finally, The Goldman Sachs Group lifted their target price on Bruker from $66.00 to $74.00 and gave the stock a "sell" rating in a report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of "Moderate Buy" and an average target price of $85.00.

Bruker Trading Up 1.9 %

Shares of BRKR stock traded up $1.40 during mid-day trading on Monday, reaching $76.47. 1,085,063 shares of the stock traded hands, compared to its average volume of 914,870. The stock's fifty day simple moving average is $84.44 and its two-hundred day simple moving average is $76.60. Bruker has a 1-year low of $53.79 and a 1-year high of $94.86. The company has a market cap of $11.11 billion, a price-to-earnings ratio of 27.81, a price-to-earnings-growth ratio of 1.79 and a beta of 1.22. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.07. The company had revenue of $721.70 million for the quarter, compared to analyst estimates of $729.88 million. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 earnings per share. On average, research analysts anticipate that Bruker will post 2.81 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Hermann Fritz Requardt sold 15,000 shares of the company's stock in a transaction on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now owns 23,147 shares in the company, valued at $2,084,618.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 28.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Several institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC purchased a new position in Bruker in the fourth quarter worth $2,384,000. Vaughan Nelson Investment Management L.P. boosted its position in Bruker by 62.5% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 315,210 shares of the medical research company's stock worth $23,161,000 after purchasing an additional 121,201 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Bruker by 79.4% in the fourth quarter. BNP Paribas Financial Markets now owns 188,201 shares of the medical research company's stock worth $13,829,000 after purchasing an additional 83,274 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of Bruker by 55.7% during the 3rd quarter. Federated Hermes Inc. now owns 138,302 shares of the medical research company's stock valued at $8,616,000 after buying an additional 49,487 shares during the last quarter. Finally, Buckhead Capital Management LLC bought a new position in shares of Bruker during the 4th quarter worth $1,634,000. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.